A detailed history of Farther Finance Advisors, LLC transactions in Altimmune, Inc. stock. As of the latest transaction made, Farther Finance Advisors, LLC holds 19 shares of ALT stock, worth $122. This represents 0.0% of its overall portfolio holdings.

Number of Shares
19
Previous 19 -0.0%
Holding current value
$122
Previous $117,000 17.09%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

SELL
$5.91 - $10.23 $455 - $787
-77 Reduced 80.21%
19 $137,000
Q1 2024

May 13, 2024

BUY
$8.22 - $13.81 $632 - $1,063
77 Added 405.26%
96 $982,000
Q4 2023

Feb 14, 2024

BUY
$2.14 - $11.62 $40 - $220
19 New
19 $214,000

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $315M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Farther Finance Advisors, LLC Portfolio

Follow Farther Finance Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Farther Finance Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Farther Finance Advisors, LLC with notifications on news.